Valeria Fantin joined Sanofi in 2021 as the Global Head of Oncology Research. She is a scientist with 20 years of industry experience in exploratory biology and oncology drug discovery and development. ​Prior to Sanofi, she led Oncology Research at Gilead Biosciences with a focus on immuno-oncology as well as mechanisms of tumorigenesis and therapy resistance. As CSO of ORIC Pharmaceuticals she established a pipeline of molecules targeting various mechanisms of therapy resistance.​

She also held leadership roles at Pfizer, where she contributed to the discovery of the brain-penetrant ALK inhibitor lorlatinib (LORBRENA^®) and to the development of the first in class CDK4/6 inhibitor palbociclib (IBRANCE^®) and, as well as at Agios, where she led the foundational work for the company’s flagship isocitrate dehydrogenase program.​ At Merck, she led translational Research efforts and contributed to the NDA filing of the first in class HDAC inhibitor vorinostat (ZOLINZA^®).

Valeria earned her B.S. in Chemistry from Universidad del Salvador-Argentina and her Ph.D. in Molecular and Cellular Biology from Dartmouth Medical School. She completed her postdoctoral training in cancer metabolism and signal transduction at Harvard Medical School and the Howard Hughes Medical Institute.